English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
2024-09-03
Next Day Disclosure Return
2024-08-30
CONNECTED TRANSACTION ANNOUNCEMENT - RENEWAL OF THE LEASE AGREEMENT
2024-08-28
Next Day Disclosure Return
2024-08-27
VOLUNTARY ANNOUNCEMENT – ON-MARKET SHARE REPURCHASE
2024-08-15
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
2024-08-15
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
2024-08-05
DATE OF BOARD MEETING
2024-08-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
2024-07-05
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 12, 2024
2024-06-12
1
2
3
4
5
6
7
PREV
4/27
NEXT